{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:25:14Z","timestamp":1760909114295,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,28]],"date-time":"2018-04-28T00:00:00Z","timestamp":1524873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H22-50"],"award-info":[{"award-number":["H22-50"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10147-018-1283-6","type":"journal-article","created":{"date-parts":[[2018,4,28]],"date-time":"2018-04-28T00:56:12Z","timestamp":1524876972000},"page":"894-899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7053-5778","authenticated-orcid":false,"given":"Kohei","family":"Nakachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Saiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotaka","family":"Shimamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,28]]},"reference":[{"key":"1283_CR1","unstructured":"Vital Statistics Japan. Ministry of Health, Labour and Welfare"},{"key":"1283_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jhbp.314","volume":"23","author":"S Ishihara","year":"2016","unstructured":"Ishihara S, Horiguchi A, Miyakawa S et al (2016) Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci 23:149\u2013157","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"1283_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/hepr.12697","volume":"46","author":"M Kudo","year":"2016","unstructured":"Kudo M, Izumi N, Ichida T et al (2016) Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res 46:372\u2013390","journal-title":"Hepatol Res"},{"key":"1283_CR4","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/cncr.10831","volume":"95","author":"T Takada","year":"2002","unstructured":"Takada T, Amano H, Yasuda H et al (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95:1685\u20131695","journal-title":"Cancer"},{"key":"1283_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2012.7352","volume":"308","author":"JP Neoptolemos","year":"2012","unstructured":"Neoptolemos JP, Moore MJ, Cox TF et al (2012) Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 308:147\u2013156","journal-title":"JAMA"},{"key":"1283_CR6","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810\u20131820","journal-title":"N Engl J Med"},{"key":"1283_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A et al (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388:248\u2013257","journal-title":"Lancet"},{"key":"1283_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00280-007-0673-7","volume":"62","author":"J Furuse","year":"2008","unstructured":"Furuse J, Okusaka T, Boku N et al (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62:849\u2013855","journal-title":"Cancer Chemother Pharmacol"},{"key":"1283_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00280-014-2543-4","volume":"74","author":"S Kobayashi","year":"2014","unstructured":"Kobayashi S, Nagano H, Sakai D et al (2014) Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study. Cancer Chemother Pharmacol 74:699\u2013709","journal-title":"Cancer Chemother Pharmacol"},{"key":"1283_CR10","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/cas.12218","volume":"104","author":"C Morizane","year":"2013","unstructured":"Morizane C, Okusaka T, Mizusawa J et al (2013) Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci 104:1211\u20131216","journal-title":"Cancer Sci"},{"key":"1283_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10120-012-0158-1","volume":"16","author":"T Aoyama","year":"2013","unstructured":"Aoyama T, Yoshikawa T, Hayashi T et al (2013) Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer. Gastric Cancer 16:133\u2013139","journal-title":"Gastric Cancer"},{"key":"1283_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Hirano S, Konishi M et al (2018) Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 105:192\u2013202","journal-title":"Br J Surg"},{"key":"1283_CR13","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1097\/SLA.0b013e3181b0fc8b","volume":"250","author":"Y Murakami","year":"2009","unstructured":"Murakami Y, Uemura K, Sudo T et al (2009) Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 250:950\u2013956","journal-title":"Ann Surg"},{"key":"1283_CR14","doi-asserted-by":"crossref","first-page":"abstr. 205","DOI":"10.1200\/JCO.2018.36.4_suppl.205","volume":"36","author":"C Morizane","year":"2018","unstructured":"Morizane C, Okusaka T, Mizusawa J et al (2018) Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: a Japan Clinical Oncology Group study (JCOG1113, FUGA-BT). J Clin Oncol 36:abstr. 205","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-018-1283-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1283-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1283-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T19:13:56Z","timestamp":1556392436000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-018-1283-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,28]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1283"],"URL":"https:\/\/doi.org\/10.1007\/s10147-018-1283-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2018,4,28]]},"assertion":[{"value":"28 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Masafumi Ikeda received honoraria from Taiho Pharmaceutical; Takuji Okusaka received research funding, consulting fee, and honoraria from Taiho Pharmaceutical; Hiroshi Ishii received research funding and honoraria from Taiho Pharmaceutical; Junji Furuse received research funding, consulting fee, and honoraria from Taiho Pharmaceutical; other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}